Medicinova (MNOV) Receivables - Net (2013 - 2025)

Medicinova (MNOV) posted quarterly Receivables - Net of $134599.0 for Q2 2025, down 86.54% quarter-over-quarter from $1.0 million in Q3 2023.

Medicinova (MNOV) Receivables - Net (2013 - 2025) Analysis & Trends

Medicinova (MNOV) has reported Receivables - Net for 6 consecutive years, with $134599.0 the latest figure, recorded in Q2 2025.

In Q2 2025, Receivables - Net changed N/A year-over-year to $134599.0; the TTM figure through Jun 2025 stood at $134599.0 (changed N/A YoY), while the FY2015 annual figure was $6.0 million, changed 0.0% from the prior year.
Receivables - Net fell to $134599.0 in Q2 2025 per MNOV's latest filing, from $1.0 million in the prior quarter.
Across five years, Receivables - Net topped out at $4.0 million in Q1 2021 and bottomed at $134599.0 in Q2 2025.
Historically, Receivables - Net has averaged $1.7 million across 3 years, with a median of $1.0 million in 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Medicinova	66.94 Mn	66.94 Mn	317,759.00

Download Data